Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares rose 50% on Thursday . The company traded as high as C$0.02 and last traded at C$0.02. Approximately 205,000 shares changed hands during trading, an increase of 5% from the average daily volume of 195,263 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Up 50.0 %
The firm has a market capitalization of C$1.99 million, a price-to-earnings ratio of -1.00 and a beta of 0.05. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The stock has a fifty day moving average of C$0.02 and a two-hundred day moving average of C$0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Recommended Stories
- Five stocks we like better than Aequus Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Stock Dividend Cuts Happen Are You Ready?
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Upcoming IPO Stock Lockup Period, Explained
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
